Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden

Noriko Fukuhara, Kenichi Ishizawa

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

The introduction of a chimeric anti-CD20 monoclonal antibody, rituximab, for the treatment of follicular lymphoma (FL) has dramatically improved the prognosis of this disease. Despite advances in therapy, the disease remains incurable with current standard therapeutic strategies. For advanced-stage and high-tumor-burden FL patients, a combination of rituximab with chemotherapy has improved the overall survival rates, and subsequent rituximab maintenance following successful rituximab-based chemotherapy induction also prolongs progression-free survival. Conversely, for advanced-stage low-tumor-burden FL patients, watchful waiting remains the appropriate approach, whereas rituximab monotherapy has also been suggested as a good alternative. However, the optimal timing of rituximab monotherapy in low-tumor-burden FL patients has not been clarified. It is important to address this issue for chemo-free treatment strategies. Furthermore, a predictive model for advanced low-tumor-burden patients is required to appropriately identify those patients who may benefit from immediate treatment. In this review, we address the current treatment approaches and present potential future management strategies for advanced-stage, low-tumor-burden patients.

Original languageEnglish
Pages (from-to)306-310
Number of pages5
JournalJapanese journal of clinical oncology
Volume49
Issue number4
DOIs
Publication statusPublished - 2019 Mar 28
Externally publishedYes

Keywords

  • follicular lymphoma
  • low tumor burden
  • rituximab monotherapy
  • watchful waiting

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint

Dive into the research topics of 'Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden'. Together they form a unique fingerprint.

Cite this